Trifecta of incoming migraine meds must be cheaper than triptans to be cost-effective — ICER
For migraine sufferers who benefit from triptans — ignore the new crop of incoming acute migraine medications — because your existing generic medicines are more effective and will likely be cheaper, a draft report by cost-effectiveness watchdog ICER suggested on Thursday.
This year, the approval of a raft of injectable migraine treatments from Teva, Eli Lilly and partners Amgen and Novartis ushered in a new era of migraine prevention. Migraine is the third most prevalent illness in the world, affecting about 39 million in the United States, and costs billions in healthcare costs and lost productivity. The market for migraine therapies is expected to hit $8.7 billion by 2026, GlobalData estimates.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 70,300+ biopharma pros reading Endpoints daily — and it's free.